| Item Type | Name |
|
Academic Article
|
Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
|
|
Academic Article
|
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.
|
|
Academic Article
|
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Interferons
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Interferon Type I
|
|
Academic Article
|
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
|
|
Academic Article
|
Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
|
|
Academic Article
|
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.
|
|
Academic Article
|
A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Update on therapeutic options for chronic myelogenous leukemia.
|
|
Academic Article
|
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes.
|
|
Academic Article
|
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
|
|
Academic Article
|
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
|
|
Academic Article
|
Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.
|
|
Academic Article
|
Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study.
|
|
Academic Article
|
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
|
|
Academic Article
|
Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia.
|
|
Academic Article
|
Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.
|
|
Academic Article
|
Treatment of myelogenous leukemia: current status and investigational options.
|
|
Academic Article
|
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.
|
|
Academic Article
|
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
|
|
Academic Article
|
Natural history and staging of chronic myelogenous leukaemia.
|
|
Academic Article
|
Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia.
|
|
Academic Article
|
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
|
|
Academic Article
|
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
|
|
Academic Article
|
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
|
|
Academic Article
|
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
|
|
Academic Article
|
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
|
|
Academic Article
|
New targeted approaches in chronic myeloid leukemia.
|
|
Academic Article
|
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
|
|
Academic Article
|
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
|
|
Academic Article
|
Experimental therapeutics for patients with myeloproliferative neoplasias.
|
|
Academic Article
|
Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals.
|
|
Academic Article
|
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
|
|
Academic Article
|
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
|
|
Academic Article
|
Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia.
|
|
Academic Article
|
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
|
|
Academic Article
|
Biologic agents for the management of hematological disorders: chronic myeloid leukemia.
|
|
Academic Article
|
Therapy of chronic myelogenous leukaemia with interferons.
|
|
Academic Article
|
The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations.
|
|
Academic Article
|
New approaches to the treatment of chronic myelogenous leukemia.
|
|
Academic Article
|
Interferon-alpha therapy for chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of chronic myelogenous leukemia.
|
|
Academic Article
|
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
|
|
Academic Article
|
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trial.
|
|
Academic Article
|
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
|
|
Academic Article
|
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
|
|
Academic Article
|
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
|
|
Academic Article
|
Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia.
|
|
Academic Article
|
Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
|
|
Academic Article
|
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
|
|
Academic Article
|
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Chronic myelogenous leukemia: update on biology and treatment.
|
|
Academic Article
|
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
|
|
Academic Article
|
Therapy of chronic myelogenous leukemia.
|
|
Academic Article
|
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?
|
|
Academic Article
|
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
|
|
Academic Article
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
|
|
Academic Article
|
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
|
|
Academic Article
|
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
|
|
Academic Article
|
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
|
|
Academic Article
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
|
|
Academic Article
|
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
|
|
Academic Article
|
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
|
|
Academic Article
|
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
|
|
Academic Article
|
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
|
|
Academic Article
|
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
|
|
Academic Article
|
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
|
|
Academic Article
|
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
|
|
Academic Article
|
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
|
|
Academic Article
|
Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells.
|
|
Academic Article
|
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
|
|
Academic Article
|
Interferon alpha in the therapy of CML.
|
|
Academic Article
|
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
|
|
Academic Article
|
Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
|
|
Academic Article
|
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
|
|
Academic Article
|
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon.
|
|
Academic Article
|
Therapy of chronic myelogenous leukemia: chemotherapy and interferons.
|
|
Academic Article
|
Therapy of chronic myelogenous leukemia with interferon.
|
|
Academic Article
|
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
|
|
Academic Article
|
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
|
|
Academic Article
|
Biologic therapy of chronic myelogenous leukemia.
|
|
Academic Article
|
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
|
|
Academic Article
|
Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
|
|
Academic Article
|
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
|
|
Academic Article
|
The natural history of chronic myelogenous leukemia in the interferon era.
|
|
Academic Article
|
Treatment of therapy-related leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Low-dose interferon-alpha in chronic myeloid leukemia.
|
|
Academic Article
|
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
|
|
Academic Article
|
Chronic myelogenous leukemia--update and future directions.
|
|
Academic Article
|
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
|
|
Academic Article
|
Chronic myelogenous leukemia: a concise update.
|
|
Academic Article
|
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.
|
|
Academic Article
|
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
|
|
Academic Article
|
Chronic myelogenous leukemia: a review.
|
|
Academic Article
|
Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha.
|
|
Academic Article
|
Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
|
|
Academic Article
|
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
|
|
Academic Article
|
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Local cutaneous necrotizing lesions associated with interferon injections.
|
|
Academic Article
|
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
|
|
Academic Article
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
|
|
Academic Article
|
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
|
|
Academic Article
|
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
|
|
Academic Article
|
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
|
Academic Article
|
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
|
|
Academic Article
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
|
Academic Article
|
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
|
|
Academic Article
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
|
Academic Article
|
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
|
|
Academic Article
|
Update: chronic myelogenous leukemia clinical practice guidelines.
|
|
Academic Article
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
|
Academic Article
|
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
|
|
Academic Article
|
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
|
|
Academic Article
|
Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.
|
|
Academic Article
|
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells.
|
|
Academic Article
|
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
|
|
Academic Article
|
Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
|
|
Academic Article
|
Advances in therapy for hairy cell leukemia. A review.
|
|
Academic Article
|
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
|
|
Academic Article
|
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
|
|
Academic Article
|
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
|
|
Academic Article
|
Therapeutic choices in younger patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
|
|
Academic Article
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
|
|
Academic Article
|
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
|
|
Academic Article
|
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
|
Academic Article
|
First-line therapy for chronic myeloid leukemia: Past, present, and future.
|
|
Academic Article
|
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
|
|
Academic Article
|
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
|
|
Academic Article
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
|
Academic Article
|
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis
|
|
Academic Article
|
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
|
|
Academic Article
|
Immunotherapy based approaches in myelofibrosis.
|
|
Academic Article
|
Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
|
|
Academic Article
|
Biology and treatment of chronic myelogenous leukemia.
|
|
Academic Article
|
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
|
|
Academic Article
|
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.
|